{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.15","value":"4.20"}]}],"title":"Physical Health Symptoms (N=209)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.00","value":"3.99"}]}],"title":"Physical Health Fatigue (N=208)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.39","value":"6.43"}]}],"title":"Physical Health Bother (N=204)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.08","value":"5.23"}]}],"title":"Physical Health Activity (N=208)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.81","value":"4.01"}]}],"title":"Emotional Health Psychological (N=208)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.59","value":"3.48"}]}],"title":"Emotional Health Fear (N=209)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.65","value":"8.32"}]}],"title":"Overall Quality of Life (N=210)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.41","value":"3.89"}]}],"title":"Social Quality of Life (N=209)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.35","value":"4.51"}]}],"title":"Women's Reproductive Health (N=71)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.54","value":"2.78"}]}],"title":"Work Quality of Life (N=75)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"292"}],"units":"Participants"}],"description":"The ITP Patient Assessment Questionnaire (ITP-PAQ) assesses ITP-specific health-related quality of life (HRQOL). This questionnaire assesses ITP specific health-related quality of life (HRQOL). The questionnaire consists of 44 items and has six domains: These domains assess the impact of ITP on Physical Health, Mental Health, Work, Social Activity, Women's Health and Overall QOL. The impact of ITP on Physical Health consists of four sub-scales, which evaluate ITP related Symptoms, Fatigue, Bother and Activity. The impact of ITP on Mental Health consists of two sub-scales, which evaluate Psychological distress and Fear in a population with ITP. Items are scored from 0-100 with higher scores indicating better HRQOL.","dispersionType":"Standard Deviation","groups":[{"description":"Romiplostim administered to adult participants subcutaneously weekly at doses up to 30 µg/kg based on platelet counts. After Amendment 1 the maximum weekly dose was reduced to 15 µg/kg, and after Amendment 2 the maximum weekly dose was reduced to 10 µg/kg. However, participants enrolled prior to Amendment 2 who were receiving \\>10 µg/kg were permitted to remain on that higher dose, but could not increase their dose. In addition, if the participant's dose was decreased, it could not be increased to \\>10 µg/kg.","id":"OG000","title":"Romiplostim in Adults"}],"paramType":"MEAN","populationDescription":"Full analysis set with available data. Patient reported outcomes were only analyzed in adult participants.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 48","title":"Change From Baseline in ITP Patient Assessment Questionnaire","type":"SECONDARY","unitOfMeasure":"scores on a scale"}